Hypertension · 2019 · 148 citations · 13 references
Public HealthMaternal HealthObstetricsHigh-risk PregnancyMaternal-fetal MedicinePrenatal DiagnosisEclampsiaHypertensive DisordersPregnancyPregnancy DiagnosisPregnancy-induced HypertensionBiomarkers Of PreeclampsiaEarly Detection Of PreeclampsiaManagement Of Pre-eclampsiaPositive Predictive ValuePreeclampsia Risk AssessmentPreeclampsia Risk PredictionPreeclampsia Risk ScreeningRandomized Clinical Trials
The ratio of maternal serum sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental growth factor) has been used retrospectively to rule out the occurrence of preeclampsia, a pregnancy hypertensive disorder, within 7 days in women presenting with clinical suspicion of preeclampsia. A prospective, interventional, parallel-group, randomized clinical trial evaluated the use of sFlt-1/PlGF ratio in women presenting with suspected preeclampsia. Women were assigned to reveal (sFlt-1/PlGF result known to clinicians) or nonreveal (result unknown) arms. A ratio cutoff of 38 was used to define low (≤38) and elevated risk (>38) of developing the condition in the subsequent week. The primary end point was hospitalization within 24 hours of the test. Secondary end points were development of preeclampsia and other adverse maternal-fetal outcomes. We recruited 370 women (186 reveal versus 184 nonreveal). Preeclampsia occurred in 85 women (23%). The number of admissions was not significantly different between groups (n=48 nonreveal versus n=60 reveal; P =0.192). The reveal trial arm admitted 100% of the cases that developed preeclampsia within 7 days, whereas the nonreveal admitted 83% ( P =0.038). Use of the test yielded a sensitivity of 100% (95% CI, 85.8–100) and a negative predictive value of 100% (95% CI, 97.1–100) compared with a sensitivity of 83.3 (95% CI, 58.6–96.4) and negative predictive value of 97.8 (95% CI, 93.7–99.5) with clinical practice alone. Use of the sFlt-1/PlGF ratio significantly improved clinical precision without changing the admission rate. Clinical Trial Registration— URL: http://www.isrctn.com . Unique identifier: ISRCTN87470468.
13
Obstetrics and Gynecology · 2013 · 3.9K citations
Medicine, Gynecology, Obstetrics +9
Anaelechi J. Onuegbu, Japhet M. Olisekodiaka, John U. Udo et al. · Medical Principles and Practice · 2015 · 2K citations · Full text
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia
Harald Zeisler, Elisa Llurba, Frédéric Chantraine et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text
Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia
Sarosh Rana, Camille E. Powe, Saira Salahuddin et al. · Circulation · 2012 · 654 citations · Full text